Waters ACQUITY UPLC Gains Approval in China


Waters Corporation’s (WAT) ACQUITY UPLC TQD system has been approved as a medical device by the Chinese Food and Drug Administration and can now be legally promoted and sold in China. This device will primarily be used for regular diagnostic applications and neonatal metabolites disease screening.

ACQUITY UPLC (Ultra Performance Liquid Chromatography/ tandem quadrupole mass spectrometry UPLC/MS/MS system)is an ultra-compact, tandem-quadrupole, mass detector-based system designed for routine UPLC/MS/MS analyses and quantitative applications featuring high levels of MS selectivity, robustness, speed, and accuracy.

The approval of ACQUITY UPLC is important for Waters as well as China. Notably, this marks the second medical device approval for Waters, the first being a neonatal screening solution which included the Waters Quattro micro mass spectrometer. On the other hand, both Chinese citizens and analytical scientists and laboratories will benefit from this sanction.

Waters Corporation is a leading analytical instrument manufacturer that designs, manufactures and sells high performance liquid chromatography (LC.V) and mass spectrometry (MS) instrument systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans.

Waters has a strong presence in the chromatography instrument industry and is currently one of the top three players in the mass spectrometry market. The company is expected to sustain its healthy organic sales growth over the next few years based on strong customer demand in the mass spectrometry and High Performance and Ultra Performance Liquid Chromatography markets.

Waters currently has a Zacks Rank #3 (Hold). Some better-ranked companies in the sector include Mettler-Toledo International Inc (MTD), PerkinElmer Inc (PKI) and Aerotech Corporation (ARTX). All three carry a Zacks Rank #2 (Buy).

Read the Full Research Report on WAT
Read the Full Research Report on PKI
Read the Full Research Report on ARTX
Read the Full Research Report on MTD

Zacks Investment Research

View Comments (1)